Climb Bio Inc (CLYM) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Climb Bio Inc stock $8.83, price $9.94, that is 11.2% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Climb Bio Inc
CLYM · USExpensive (fair value 11% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range $1.13 – $28.61 · fair‑value band $6.62 – $11.03 · the $9.94 price screens above the $8.83 fair value. As of Nov 11, 2026.
Every Wednesday you see whether Climb Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Show moreShow less
It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.
In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases.
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Stock analysis
Climb Bio Inc (CLYM) currently trades at $9.94, while our estimate is $8.83, 11% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $6.62 (bear) to $11.03 (bull), the price of $9.94 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Climb Bio Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$59.9M in FY2025.
Key figures
Market cap $757M Small · EPS (TTM) $−0.8700 · Return on equity −29.3% · Return on assets (EBIT) −33.7% (5-year average) · Free cash flow −$54.5M · Net cash $35.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 506% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −11%, CLYM screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 2 officers or directors sold shares worth $1.8M and none bought.
- SaleStephen Basil ThomasDirector3× since Feb 12, 2026: 250,000 shares, avg. $8.98$2.2MSep 15, 202610b5-1 plan
- SaleAoife BrennanPresident and CEO, Director30,902 shares at $13.17$406,979Jun 29, 202610b5-1 plan
- BuyRA Capital Healthcare Fund LPDirector, 10% owner7,111 shares at $3.50$24,889Jan 5, 2026
- BuyPeter KolchinskyDirector, 10% owner314,561 shares at $2.40$754,737Dec 12, 2025
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Climb Bio Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs CLYM |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs CLYM |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs CLYM |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs CLYM |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs CLYM |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs CLYM |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs CLYM |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs CLYM |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs CLYM |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs CLYM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Climb Bio Inc (CLYM) overvalued or undervalued?
What is the fair value of CLYM?
What is the quality score of CLYM?
What is the price target for Climb Bio Inc (CLYM)?
What is the Climb Bio Inc stock forecast for 2026?
What is the intrinsic value of Climb Bio Inc (CLYM)?
Is Climb Bio Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of CLYM?
How much is Climb Bio Inc worth?
What do the bullish and bearish scenarios say about CLYM?
How solid is the balance sheet of Climb Bio Inc (CLYM)?
How far is CLYM from its 52-week high?
Which stocks are comparable to Climb Bio Inc?
Is Climb Bio Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Climb Bio Inc (CLYM)?
What should I pay attention to with Climb Bio Inc right now?
Key figures of Climb Bio Inc
How large is the market capitalisation of Climb Bio Inc (CLYM)?
What are the earnings per share of Climb Bio Inc (CLYM)?
What is the return on equity of Climb Bio Inc (CLYM)?
What is the EBIT return on assets of Climb Bio Inc (CLYM)?
How much free cash flow does Climb Bio Inc (CLYM) generate?
How much net cash does Climb Bio Inc (CLYM) hold?
Watch Climb Bio Inc in the live analysis
One click puts Climb Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.